SARCOPENIC OBESITY IN THE ERA OF INCRETIN-BASED THERAPIES: DIAGNOSTIC CHALLENGES, THE RISK OF MUSCLE MASS LOSS, AND PREVENTION STRATEGIES
Authors:
- Anna WolszczakAWAnna Wolszczak
- Weronika MartynowskaWMWeronika Martynowska
- Michał HajtMHMichał Hajt
- Dastin MisiaszekDMDastin Misiaszek
- Alicja GraczykAGAlicja Graczyk
- Piotr CiecierskiPCPiotr Ciecierski
- Natalia GrabowskaNGNatalia Grabowska
- Jakub MotorJakub Motor
- Paulina Patrycja TurzyńskaPTPaulina Patrycja Turzyńska
Open Access
- 2 July 2026
- journal article
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (3(51))
Abstract
Introduction and purpose. Sarcopenic obesity (SO) is defined by the coexistence of excess adiposity and reduced muscle mass and function and is associated with disability, frailty, cardiometabolic disease, and increased mortality. This review aims to summarize current evidence on the definition and diagnosis of SO, assess the effects of incretin-based therapies on body composition, with a focus on practical strategies to reduce the risk of clinically relevant muscle loss during obesity treatment. Material and methods. This manuscript was prepared as a structured narrative review based on publications identified in PubMed/MEDLINE, Google Scholar, and the Cochrane Library. Results. Current evidence suggests that semaglutide and tirzepatide produce significant and sustained reductions in body weight and fat mass, including visceral adipose tissue, while also being associated with a decrease in absolute lean body mass. These changes should not be interpreted automatically as clinically relevant skeletal muscle loss. However, older adults, frail individuals, and patients with low muscle reserve are more susceptible, especially without adequate protein intake, resistance exercise, and regular monitoring. Conclusions. Incretin-based therapies represent a major advance in obesity treatment; however, in patients at risk of SO, they should be used within a multimodal strategy aimed at preserving muscle mass and function.Keywords
This publication has 33 references indexed in Scilit:
- Nutritional considerations with antiobesity medicationsObesity, 2024
- Sarcopenic obesity in older adults: a clinical overviewNature Reviews Endocrinology, 2024
- Sarcopenic Obesity and Risk of Disability in Community-Dwelling Japanese Older Adults: A 5-Year Longitudinal StudyJournal of the American Medical Directors Association, 2023
- Global prevalence of sarcopenic obesity in older adults: A systematic review and meta-analysisClinical Nutrition, 2021
- Once-Weekly Semaglutide in Adults with Overweight or ObesityNew England Journal of Medicine, 2021
- Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trialDiabetologia, 2020
- International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and ManagementThe Journal of nutrition, health and aging, 2018
- Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategiesNature Reviews Endocrinology, 2018
- Aerobic or Resistance Exercise, or Both, in Dieting Obese Older AdultsNew England Journal of Medicine, 2017
- Evidence-Based Recommendations for Optimal Dietary Protein Intake in Older People: A Position Paper From the PROT-AGE Study GroupJournal of the American Medical Directors Association, 2013